Cipla’s revenues moderate, grow by 18% to Rs2,103 crore
Moneylife Digital Team 06 February 2013

Cipla’s domestic and international business grew while its international API formulations business shrunk

Cipla’s gross revenues grew by 18% year-on-year to Rs2,103 crore for the quarter  ended December 2012 compared to Rs1,783 crore for the same period last year. Its operating margins grew by 25.4% to Rs493 crore, up from Rs393 crore in for the corresponding period last year.

 

Similarly Cipla’s net profit rose 25.5% to Rs339 crore, up from Rs270 crore it recorded during Q3 of the 2011-2012 fiscal.

 

Exports of formulations, for its international business, grew by 38% to Rs969 crore during Q3FY13, when compared to Rs702 crore. However, exports of APIs fell 16% to Rs137 crore from Rs164 crore.

 

The growth in exports revenues was primarily due to growth in anti-depressants, anti-malarials, anti-retroviral and anti-asthma segments, while growth in domestic market were due to increased anti-asthma, antibiotics and cardiovascular therapy sales.

 

Cipla has a global turnover of $1.4 billion and serves doctors and patients in over 170 countries. It has earned a name for maintaining one global standard across all its products and services.

Comments
Array
Free Helpline
Legal Credit
Feedback